MoneyWorks4Me

SMS Pharmaceuticals submits annual report

01 Oct 2019 Evaluate

Pursuant to Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, SMS Pharmaceuticals has informed about submission of a copy of the Annual Report of the Company for the financial year 2018-2019, which was approved and adopted by the members at their Annual General Meeting held on 30th Day of September, 2019 at 09:00 am, at JRC Conventions and Trade Fairs, Survey No.4, Narne Road, Jubilee Hills, Hyderabad - 500008.

The above information is a part of company’s filings submitted to BSE.

SMS Pharmaceuticals Share Price

377.30 20.10 (5.63%)
07-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1949.00
Dr. Reddys Labs. 1172.00
Cipla 1472.00
Lupin 2360.00
Zydus Lifesciences 1115.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: